Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica recommences trading after securing funding, shares up 13%

The company recommenced trading today up 13.3% to 3.4 cents per share.
highway sign reading 'funding, next exit'
The funds will be used to deliver a number of milestones over the coming 12 months

Phylogica Ltd (ASX:PYC) has recommenced trading on the ASX today after a successful recapitalisation that involved a $9.12 million share placement priced at 3 cents.

Firm commitments for the placement funds have been received which will be used to accelerate its path towards first in human trials of its Cell Penetrating Peptides (CPPs).

The placement will occur in two tranches with the first tranche of $4.4 million to be complete on 21 September 2018.

READ: Phylogica achieves a milestone in intracellular drug delivery

Phylogica is using its peptide library to develop a drug delivery platform capable of reaching the highest value drug targets located inside cells.

The company’s drug delivery platform transports drugs into the intracellular environment where most diseases are.

The company aims to find drugs that can get delivered into that intracellular environment and be the delivery mechanism for that drug.

Clear strategy for building shareholder value

Over the next 12 months Phylogica aims to deliver:

- Second generation CPPs from the recently enriched peptide libraries;
- Evaluation of the ability of CPPs to deliver a drug cargo in a therapeutic model of disease (animal model); and
- Initiation of the enabling studies required to lodge an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA).

View full PYC profile View Profile

Phylogica Limited Timeline

Newswire
October 06 2015
Newswire
November 25 2014

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use